CellRapeutics™ Leukopak from Relapsing-Remitting Multiple Sclerosis Donor (XS-0426-XU291)

Name: CellRapeutics™ Leukopak from Relapsing-Remitting Multiple Sclerosis Donor
SKU: XS-0426-XU291
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This Leukopak provides a comprehensive leucocyte profile harvested from donors clinically diagnosed with Relapsing-Remitting Multiple Sclerosis. The cellular composition captures the dynamic fluctuations of the systemic immune system characteristic of this disease, featuring an enriched repertoire of autoreactive T-cell subsets and memory B cells primed for neuro-antigen recognition. It serves as a high-yield source for investigating the mechanisms of episodic blood-brain barrier penetration and the efficacy of disease-modifying therapies on peripheral immune cell activation.

Specific Inquiry

Add to Cart

Donor Information

Product Name
CellRapeutics™ Leukopak from Relapsing-Remitting Multiple Sclerosis Donor

Cat. No.
XS-0426-XU291

Donor Age
Young Adult

Donor Health
Clinically diagnosed with RRMS. The leukocyte population is characterized by a phasic neuro-inflammatory profile, showing episodic expansion of Th1/Th17 effector subsets and a high frequency of immune cells with enhanced blood-brain barrier migratory potential.

Ethnicity
Diverse backgrounds available, predominantly Caucasian.

Anticoagulant
Acid Citrate Dextrose, prioritized to capture the dynamic shift in T cell subsets while maintaining their quiescent or activated states.

Additional Donor Information
Each lot features a Leukopak from donors with RRMS. Profiles include relapse frequency and history of disease-modifying therapies, ideal for studying the episodic nature of autoimmune neuro-inflammation.

Clinical Profile
Confirmed RRMS diagnosis, time since last relapse, EDSS score, and detailed history of disease-modifying therapies.

Additional Information

Medication History
Available upon request. Comprehensive records of Disease-Modifying Therapies including injectables, orals, or high-efficacy infusion therapies.

Formulation
Cryopreserved or Fresh options available.

Cell Purity
>90%

Cell Viability
>90%

Mycoplasma Testing
Negative

Sterility Testing
Negative

Genetic Stability Testing
The donor cells maintain their native genetic profile, exhibiting no karyotypic abnormalities or chromosomal instabilities typically associated with prolonged ex vivo expansion.

Application
Drug Discovery, Immuno-oncology Research

Research Use Only
RUO

Quality Control
Each product batch is strictly validated for high cellular viability, specific immune cell counts, and pathogen-free safety, ensuring consistent clinical phenotypes and ethical compliance for advanced immunological research.

Storage
Store fresh Leukopaks at 2°C to 8°C for immediate use, cryopreserved samples must be kept in liquid nitrogen vapor phase below -150°C.

Shiping
Dry Ice

Handling Notes
Process fresh cells within 48 hours or perform rapid thawing of cryovials in a 37°C water bath followed by gradual dilution to maximize recovery.

Warnings
Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.

Size
Full Bag, Half Bag

Keywords
CellRapeutics™ Leukopak from Relapsing-Remitting Multiple Sclerosis Donor, Leukopak, Relapsing-Remitting Multiple Sclerosis

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Leukopak from Relapsing-Remitting Multiple Sclerosis Donor (XS-0426-XU291). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.